EUCTR2017-002751-28-NL进行中（未招募）1 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects with Multiple Osteochondromas - MO-Ped Trial
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written, signed, and dated informed subject/parent consent and age appropriate assent (performed according to local regulations).
- •2. A clinical diagnosis of MO with a disease-causing Ext1 or Ext2 mutations confirmed by a central laboratory.
- •3. Male and female subjects with a chronological age of 2-14 years, inclusive.
- •4. Female subjects must be premenarchal at screening.
- •5. Bone age at screening of =14 years, 0 months per the Greulich-Pyle method as assesed by a central reader.
- •6. Symptomatic MO, defined as the occurrence of any one of the following at screening:
- •Five or more clinically-evident OCs and the presence of a new or enlarging OC in the preceding 12 months.
- •Five or more clinically-evident OCs and the presence of a painful OC.
- •A skeletal deformity.
- •A joint limitation.
- •Prior surgery for a MO-related complication.
- •7. If a subject had a prior surgery for MO, the subject cannot be screened until 8 weeks post-surgery to allow for stabilization of symptoms. Surgical orthopedic implants are allowed if they were in situ for =12 weeks prior to the baseline MRI.
- •8. If a subject is currently receiving pain medications, the dose must be stable (ie, <20% variance) for 2 weeks prior to screening.
- •9. The ability to undergo whole body MRI with or without sedation/general anesthesia.
- •10. Male and female subjects with a Tanner stage of =2 must agree to use two highly effective methods of birth control during treatment, and for 1 month after treatment discontinuation, unless they commit to true abstinence from heterosexual sex. Sexually active FOCBP must also agree to start effective methods of birth control at screening.
- •11. Subjects must be accessible for treatment with study drug and follow-up.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 240
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. A weight <10 kg.
- •2. Other known syndromic conditions such as Langer-Giedion or Potocki Shaffer.
- •3. Any subject with neurologic signs suggestive of spinal cord impingement.
- •4. If subject is currently using vitamin A or beta carotene, multivitamins containing vitamin A or beta carotene, or herbal preparations, fish oil, and unable or unwilling to discontinue use of these products during palovarotene treatment. For eligibility, no washout is required prior to the first dose of study drug.
- •5. Exposure to synthetic oral retinoids within 4 weeks prior to enrollment.
- •6. Concurrent treatment with tetracycline or any tetracycline derivatives, due to the potential increased risk of pseudotumor cerebri.
- •7. History of allergy or hypersensitivity to retinoids, gelatin or lactose (other than lactose intolerance).
- •8. Concomitant medications that are strong inhibitors or inducers of cytochrome P450 (CYP450) 3A4 activity.
- •9. Amylase or lipase >2 times the above the upper limit of normal (>2×ULN) or with a history of chronic pancreatitis.
- •10. Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5x ULN.
- •11. Fasting triglycerides >400 mg/dL with or without therapy.
- •12. Subjects with uncontrolled cardiovascular, renal, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or other significant disease. These include subjects requiring glucocorticoid at doses >0.2mg/kg or up to 10 mg prednisone equivalent daily.
- •13. Subjects experiencing suicidal ideation (type 4 or 5) or any suicidal behavior within the past month or any suicidal behavior within the past year as defined by the Columbia-Suicide Severity Rating Scale (C SSRS).
- •14. Subjects unable or unwilling to complete the study or all study-related procedures, including imaging.
- •15. Any surgical implant that is contraindicated for MRI. Dental braces are permitted.
- •16. Participation in any clinical research study within 4 weeks prior to enrollment or simultaneous participation in any clinical research study.
- •17. Any reason that, in the opinion of the Investigator, would lead to the inability of the subject and/or family to comply with the protocol.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects with Idiopathic Detrusor OveractivityIdiopathic Detrusor Overactivity (Overactive Bladder)EUCTR2005-005868-93-GBAVERA PHARMACEUTICALS INC.62
进行中（未招募）
1 期
A study to assess the safety and effectiveness of enzalutamide in patients with advanced hepatocellular carcinomaMale and female subjects with HCC of any etiology who have progressed on or were intolerant to sorafenib or other anti-VEGF therapy in the advanced settingMedDRA version: 18.1Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004283-37-ESAstellas Pharma Global Development, Inc.165
进行中（未招募）
1 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects with Idiopathic Detrusor OveractivityIdiaopathic Detrusor Overactivity (Overactive Bladder)EUCTR2005-005868-93-NLAVERA PHARMACEUTICALS INC.62
进行中（未招募）
1 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects with Severe HypertriglyceridemiaSevere Hypertriglyceridemia (SHTG)MedDRA version: 20.1Level: LLTClassification code 10020870Term: HypertriglyceridemiaSystem Organ Class: 100000004861EUCTR2020-000641-13-HU89bio, Inc.90
进行中（未招募）
1 期
A study to test the efficacy and safety of the drug INCB054707 on a skin condition called Prurigo NodularisPrurigo NodularisMedDRA version: 20.0Level: LLTClassification code 10037084Term: Prurigo nodularisSystem Organ Class: 100000004858EUCTR2021-006329-23-ESIncyte Corporation140